BOCA RATON, FL--(Marketwire - August 07, 2009) - David Fater, CEO of Vicor Technologies, Inc.
(OTCBB: VCRT), today announced that Andriy Batchinsky, MD, a researcher
with the U.S. Army Institute of Surgical Research (USAISR), will present
findings from trials of Vicor's PD2i VS (Vital Sign) that have been
performed under a collaborative agreement between Vicor and the USAISR at
Smart Monitoring 2009 and the ATACCC 2009 Conference on August 10-12, 2009
in St. Petersburg Beach, Florida. Smart Monitoring, which immediately
precedes the ATACCC Conference, is a forum for open discussions focused on
vital signs monitoring for combat casualty care. The ATACCC (Advanced
Technology Applications for Combat Casualty Care) Conference is the premier
scientific meeting of the Department of Defense (DOD). Vicor is a
biotechnology company focused on the commercialization of innovative,
non-invasive medical devices and diagnostics using its patented,
proprietary PD2i algorithm and software to stratify patients at risk of
sudden cardiac death and trauma victims in need of life saving
Dr. Batchinsky will make two presentations. The first -- "Toward Automated
Detection of Life-threatening Injury Using Comprehensive Assessment of the
Electrocardiogram" -- will be presented at the Smart Monitoring 2009
Conference during a panel discussion entitled, "New Vital Signs, Predictive
Variables and Indices," on Sunday, August 9. The second -- "Does Heart
Rate Complexity Add to Traditional Vital Signs for Trauma Patient Triage?"
-- will be presented at the ATACCC 2009 Conference on Tuesday, August 11.
Both presentations will a) detail the use of Vicor's PD2i VS as a new vital
sign diagnostic that more accurately risk stratifies trauma severity and
the probability of survival in the critically injured, and b) provide a
review of findings from trials conducted under the Collaborative Research
and Development Agreement (CRADA) between Vicor and the USAISR begun in
"We're extremely pleased and honored to have our PD2i VS diagnostic
presented at Smart Monitoring 2009 and the ATACCC 2009 Conference by Dr.
Batchinsky, who has been actively involved in all of the clinical trials of
the PD2i VS conducted under the CRADA," stated Mr. Fater. "As we steadily
advance commercialization of our PD2i diagnostics, visibility at
prestigious conferences such as these enhances our opportunity to explore
new strategic relationships and collaborative efforts that may enable us to
identify new applications for the PD2i," he continued. "Additional
information about the PD2i VS and trials demonstrating its effectiveness to
risk stratify trauma severity -- along with information about our other
PD2i diagnostics -- may be found at our new website: www.vicortech.com,"
Mr. Fater concluded.
Sponsored by the Resuscitation Research Laboratory of the University of
Texas Medical Branch, Smart Monitoring addresses the need for new
technologies requiring innovation from government, academia, and industry
by providing a forum for communication between industry representatives and
expert medical caregivers.
The ATACCC addresses critical advances in trauma medicine and the unique
medical needs of the war fighter, with a focus on the growing and changing
operational issues and identifies technologies available today and in the
future that can be used to meet these increasingly complex goals.
Additional information about the ATACCC 2009 Conference may be found at
About Vicor Technologies, Inc.
Vicor Technologies is a development-stage biotechnology company creating
innovative non-invasive diagnostics employing its patented, proprietary
point correlation dimension algorithm (PD2i.) The PD2i is a deterministic,
non-linear measure that analyzes electrophysiological potentials to predict
future pathological events with a high degree of accuracy in target
Vicor currently has three products employing the PD2i algorithm. The PD2i
Analyzer, which has FDA 510(k) marketing clearance, measures heart rate
variability and will be commencing a clinical trial to determine its
efficacy to detect the presence of diabetic autonomic neuropathy (DAN). The
PD2i VS (Vital Sign), in clinical trials under a collaborative effort with
the U.S. Army Institute for Surgical Research
(http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian
trauma victims. The PD2i CA (Cardiac Analyzer), in multiple clinical
trials, identifies patients at risk of suffering sudden cardiac death.
Vicor anticipates additional applications employing the PD2i to enable
early detection and risk stratification for a variety of other disorders
and diseases. Additional information is available at www.vicortech.com.
The appearance of name-brand institutions or products in this media release
does not constitute endorsement by the U.S. Army Medical Research and
Materiel Command, the Department of the Army, Department of Defense or the
U.S. Government of the information, products or services contained therein.
Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans
and expectations that are subject to uncertainties and risks, which could
cause our future results to differ materially. The following factors,
among others, could cause our actual results to differ: our ability to
obtain FDA approval of the PD2i VS for military and civilian applications
and the PD2i Cardiac Analyzer, our ability continue to receive financing
sufficient to continue operations and complete the critical clinical
trials; our ability to continue as a going concern; our ability to
successfully develop products based on our technologies; our ability to
obtain and maintain adequate levels of third-party reimbursement for our
products; the impact of competitive products and pricing; our ability to
receive regulatory approval for our products; the ability of third-party
contract research organizations to perform preclinical testing and clinical
trials for our technologies; the ability of third-party manufacturers to
manufacture our products; our ability to retain the services of our key
personnel; our ability to market and sell our products successfully; our
ability to protect our intellectual property; product liability; changes in
federal income tax laws and regulations; general market conditions in the
medical device and pharmaceutical industries; and other matters that are
described in Vicor's Annual Report on Form 10-K for the fiscal year ended
December 31, 2008 and subsequent filings with the Securities and Exchange
Commission. Forward-looking statements in this press release speak only
as of the date of the press release, and we assume no obligation to update
forward-looking statements or the reasons why actual results could differ.